Transient receptor potential (TRP) channel modulators, specifically TRPV1 antagonists and TRPM8 agonists, show promise as effective and safe treatments for dry eye disease, according to a study.
Researchers conducted a comprehensive review of randomized clinical trials across 7 databases, including 6 studies with 884 participants.
The trials examined TRPV1 antagonists and TRPM8 agonists. There were significant improvements in subjective symptom scores, corneal staining, tear production (measured by non-anesthetic Schirmer’s test), and tear meniscus height. Quality of life and daily functioning also showed notable enhancement. Furthermore, TRP modulators effectively reduced conjunctival redness and maintained a safety profile comparable to vehicle controls, with no increase in adverse events.
Reference
Duan X, Ju M, Liu X, et al. Efficacy and safety of transient receptor potential channel modulators for dry eye: A systematic review and meta-analysis. Cont Lens Anterior Eye. 2025;102347. doi: 10.1016/j.clae.2024.102347. Epub ahead of print. PMID: 39753447.
Related Content
